Frontier Capital Management Co. LLC Sells 37,836 Shares of Hologic, Inc. (NASDAQ:HOLX)

Frontier Capital Management Co. LLC lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 5.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 696,860 shares of the medical equipment provider's stock after selling 37,836 shares during the period. Frontier Capital Management Co. LLC owned approximately 0.31% of Hologic worth $50,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group increased its holdings in shares of Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 145 shares during the period. Smartleaf Asset Management LLC grew its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC increased its stake in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 169 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after acquiring an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc boosted its position in shares of Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after acquiring an additional 200 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Up 4.3 %

Hologic stock opened at $55.41 on Thursday. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The stock has a market cap of $12.43 billion, a PE ratio of 17.48, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a fifty day moving average of $59.69 and a 200 day moving average of $68.69.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.03 earnings per share. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HOLX shares. Royal Bank of Canada lowered their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Raymond James reissued an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday. Finally, Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $79.85.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.